Detalles de la búsqueda
1.
Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.
J Pathol
; 262(3): 271-288, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38230434
2.
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
J Pathol
; 260(5): 514-532, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37608771
3.
Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
J Pathol
; 260(5): 498-513, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37608772
4.
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Breast Cancer Res
; 24(1): 61, 2022 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096872
5.
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer.
Breast Cancer Res Treat
; 190(2): 295-305, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34524591
6.
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Lancet Oncol
; 21(11): 1443-1454, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33152284
7.
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Breast Cancer Res
; 22(1): 2, 2019 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-31892336
8.
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Breast Cancer Res Treat
; 175(1): 149-163, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30680659
9.
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Breast Cancer Res
; 20(1): 103, 2018 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30180877
10.
Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials.
Acta Oncol
; 57(1): 38-43, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29172851
11.
Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.
Breast Cancer Res Treat
; 165(2): 355-364, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28612227
12.
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
Breast Cancer Res
; 18(1): 39, 2016 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27036195
13.
Defining breast cancer intrinsic subtypes by quantitative receptor expression.
Oncologist
; 20(5): 474-82, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25908555
14.
Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
BMC Med
; 13: 303, 2015 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-26684470
15.
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.
Oncologist
; 18(2): 123-33, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23404817
16.
Use of mutation profiles to refine the classification of endometrial carcinomas.
J Pathol
; 228(1): 20-30, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22653804
17.
Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers.
Nat Commun
; 14(1): 4017, 2023 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37419892
18.
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Clin Cancer Res
; 29(18): 3691-3705, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37574209
19.
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes.
J Clin Oncol
; 41(26): 4192-4199, 2023 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37672882
20.
The proteomic landscape of soft tissue sarcomas.
Nat Commun
; 14(1): 3834, 2023 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37386008